|
1
|
Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.
|
J Clin Oncol
|
2005
|
2.37
|
|
2
|
How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
|
Clin Cancer Res
|
2005
|
1.56
|
|
3
|
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
|
Cancer Res
|
2005
|
1.34
|
|
4
|
Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
|
Clin Cancer Res
|
2006
|
1.26
|
|
5
|
DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
|
Breast Cancer Res Treat
|
2007
|
1.08
|
|
6
|
Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
|
Clin Cancer Res
|
2003
|
1.04
|
|
7
|
The prognostic value of BCAR1 in patients with primary breast cancer.
|
Clin Cancer Res
|
2004
|
1.04
|
|
8
|
CHEK2 1100delC and male breast cancer in the Netherlands.
|
Breast Cancer Res Treat
|
2008
|
0.93
|
|
9
|
Development of an ELISA for measurement of BCAR1 protein in human breast cancer tissue.
|
Clin Chem
|
2004
|
0.79
|